According to the US health regulator USFDA, Ohms Laboratories started the voluntary recall in February this year.
"An unacceptable level of blister defects have been identified in Loratadine and Pseudoephedrine Sulfate Extended release tablets, 10 mg/240 mg," the USFDA said.
The recall by Ohms comes at a time when the US Food and Drug Administration (USFDA) has banned all the four plants of Ranbaxy in India from exporting drugs to the US.
In January, the USFDA prohibited Ranbaxy from providing active pharmaceutical ingredients from Toansa plant to other companies, including other Ranbaxy facilities, that make products for American consumers.
The USFDA imposed an import alert on Ranbaxy's Mohali plant in Punjab for violating current good manufacturing norms last September. Ranbaxy's key facilities at Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh have been under a US import alert since 2008.
Last year in May, Ranbaxy pleaded guilty to 'felony charges' related to the manufacture and distribution of certain 'adulterated' drugs made at the Dewas and Paonta Sahib units and agreed to pay $500 million to US authorities as penalty.
This followed a series of actions by the USFDA, which in 2008 banned the import of 30 generic drugs produced by Ranbaxy at the two plants for violation of manufacturing norms.